ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

    NEXT STORY
    Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER
    PREV STORY
    TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Horizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference

    DUBLIN, Ireland, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

    author_avatar
    NASDAQ Market News

    AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit

    author_avatar
    NASDAQ Market News